Dataset Information


ADAM10 expression and promoter haplotype in Alzheimer's disease.

ABSTRACT: Alzheimer's disease is confirmed at autopsy according to the accumulation of brain neuritic plaques and neurofibrillary tangles in the brain. Neuritic plaques contain amyloid-? (A?) and lower levels of A? correspond to an increase in ADAM10 ?-secretase activity. ADAM10 ?-secretase activity produces a soluble amyloid precursor protein (APP) alpha (sAPP?) product and negates the pathological production of A?. In this investigation, it was hypothesized that genetic variation with the ADAM10 promoter is associated with ADAM10 expression levels as well as cerebrospinal fluid sAPP? levels. Results from this investigation suggest that the ADAM10 rs514049-rs653765 C-A promoter haplotype is associated with: (1) higher CSF sAPP? levels in cognitively normal controls compared with Alzheimer's disease (AD) patients, (2) higher postmortem brain hippocampus, but not cerebellum, ADAM10 protein levels in subjects with low plaque scores compared with those with high plaque scores, and (3) higher promoter activity for promoter-only reporter constructs compared with promoter 3' untranslated region (3'UTR) constructs in the human neuroblastoma SHSY5Y cell line, but not in HepG2 or U118 cell lines. Taken together, these findings suggest that ADAM10 expression is modulated according to a promoter haplotype that is influenced in a brain region- and cell type-specific manner.


PROVIDER: S-EPMC3391324 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4988779 | BioStudies
2018-01-01 | S-EPMC5778060 | BioStudies
2013-01-01 | S-EPMC4105199 | BioStudies
2020-01-01 | S-EPMC7068801 | BioStudies
2013-01-01 | S-EPMC4233972 | BioStudies
1000-01-01 | S-EPMC6306343 | BioStudies
2015-01-01 | S-EPMC4373036 | BioStudies
2017-01-01 | S-EPMC5673635 | BioStudies
2020-01-01 | S-EPMC7037359 | BioStudies
2018-01-01 | S-EPMC6282062 | BioStudies